Dimapur News Desk

Diffuse Large B-cell Lymphoma (DLBCL) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

 Breaking News
  • No posts were found

Diffuse Large B-cell Lymphoma (DLBCL) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

May 28
22:10 2021
Diffuse Large B-cell Lymphoma (DLBCL) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

DelveInsight Business Research LLP
DelveInsight’s “Diffuse Large B-cell Lymphoma (DLBCL)–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Diffuse Large B-cell Lymphoma (DLBCL), historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma (DLBCL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Diffuse Large B-cell Lymphoma (DLBCL)-Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Diffuse Large B-cell Lymphoma (DLBCL)–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Diffuse Large B-cell Lymphoma (DLBCL), historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma (DLBCL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  1. DLBCL cases most commonly affect middle-aged and older adults. In comparison, they are relatively less common in children and young adults. It was observed that the age group with the highest incidence among the 7MM was 65–74 years in 2020. Patients of the age group 55–64 years were observed to be the second-highest in 2020.
  2. Among the EU5 countries, Germany had the highest incident population of DLBCL with 7,675 cases, followed by the United Kingdom and France, while Spain had the lowest incident cases in 2020.
  3. Japan had 9,788 cases for DLBCL in 2020, which accounted for ~14% of the total 7MM patient population of DLBCLDLBCL has many subtypes and according to DelveInsight’s analysis, DLBCL, NOS (Not-otherwise specified DLBCL) accounts for the majority of the B-cell patient population. In the United States, 26,540 cases were observed for DLBCL, NOS in 2020.

Key benefits of the report:

1.The Diffuse Large B-cell Lymphoma (DLBCL) market report covers a descriptive overview and comprehensive insight of the Diffuse Large B-cell Lymphoma (DLBCL) epidemiology and Diffuse Large B-cell Lymphoma (DLBCL) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2.The Diffuse Large B-cell Lymphoma (DLBCL) market report provides insights into the current and emerging therapies.

3.Diffuse Large B-cell Lymphoma (DLBCL) market report provides a global historical and forecasted market covering drug outreach in 7MM.

4.The Diffuse Large B-cell Lymphoma (DLBCL) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Diffuse Large B-cell Lymphoma (DLBCL) market.

Request for sample pages: https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market

Diffuse Large B-cell Lymphoma (DLBCL): Overview

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that affects B-lymphocytes. It develops when B-lymphocytes become abnormal. It is a mature B-cell neoplasm arising from the germinal center & post germinal center B-cells.

The etiology of DLBCL is complex and multifactorial. DLBCL can arise de-novo or from the transformation of indolent diseases like chronic lymphocytic lymphoma/small lymphocytic lymphoma (so-called Richter’s transformation), follicular lymphoma, and marginal zone lymphoma.

The first sign of DLBCL includes painless, rapid swelling in the neck, underarms, or groin that is caused by enlarged lymph nodes. For some patients, the swelling may be painful. Other symptoms may include night sweats, fever, and unexplained weight loss. Patients may also notice fatigue, loss of appetite, shortness of breath, or pain. 

The key players involved in the Diffuse Large B-cell Lymphoma (DLBCL) market:

1. Acerta Pharma BV/ Astrazeneca

2. Genmab and AbbVie

3. MorphoSys AG

4. TG Therapeutics

5. Seattle Genetics/Takeda)

6. ADC Therapeutics

7. Celgene/Juno Therapeutics

The launch of the emerging therapies is expected to significantly impact the  Diffuse Large B-cell Lymphoma (DLBCL) treatment scenario in the upcoming years:-

Drug covered

  1. Acalabrutinib 
  2. Epcoritamab
  3. Tafasitamab
  4. Ublituximab+Umbralisib
  5. Brentuximab Vedotin
  6. Loncastuximab Tesirine
  7. JCAR017

Request a free sample report @https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Diffuse Large B-cell Lymphoma (DLBCL) Patient Share (%) Overview at a Glance

5. Diffuse Large B-cell Lymphoma (DLBCL) Market Overview at a Glance

6. Diffuse Large B-cell Lymphoma (DLBCL) Disease Background and Overview

7. Diffuse Large B-cell Lymphoma (DLBCL) Epidemiology and Patient Population

8. Country-Specific Patient Population of Diffuse Large B-cell Lymphoma (DLBCL) 

9. Diffuse Large B-cell Lymphoma (DLBCL) Current Treatment and Medical Practices

10. Unmet Needs

11. Diffuse Large B-cell Lymphoma (DLBCL) Emerging Therapies

12. Diffuse Large B-cell Lymphoma (DLBCL) Market Outlook

13. Country-Wise Diffuse Large B-cell Lymphoma (DLBCL) Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Diffuse Large B-cell Lymphoma (DLBCL) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Diffuse Large B-cell Lymphoma (DLBCL)-Pipeline Insights, 2021

“Diffuse Large B-cell Lymphoma (DLBCL)-Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Diffuse Large B-cell Lymphoma (DLBCL) market. A detailed picture of the Diffuse Large B-cell Lymphoma (DLBCL) pipeline landscape is provided, which includes the disease overview and Diffuse Large B-cell Lymphoma (DLBCL) treatment guidelines.

Diffuse Large B-cell Lymphoma (DLBCL)-Epidemiology Forecast to 2030

DelveInsight’s ‘Diffuse Large B-cell Lymphoma (DLBCL)-Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Diffuse Large B-cell Lymphoma (DLBCL){;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spawere n, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/dimapurnewsdesk/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share